However, as with any major medical treatment, the transition from clinical trials to the “real world” often leads to questions that aren’t always covered in a standard doctor’s visit. Patients are ...

Almost 30,000 people in England with chronic obstructive pulmonary disease (COPD) could soon have access to a biologic treatment, Sanofi and Regeneron's Dupixent, after it was recommended for use by ...

Chong Kun Dang said on the 14th that its Dupixent (ingredient dupilumab) biosimilar CKD-706 received phase 1 clinical trial approval from the European Medicines Agency (EMA) and the U.K. Medicines and ...

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed COPD refers to a group of lung disorders caused by obstruction or narrowing of the airways. COPD ...

Sanofi has debuted the long-awaited results from two Phase III studies of its potential Dupixent (dupilumab) successor, amlitelimab, in atopic dermatitis (AD) – with the data having garnered a ...

In these two phase 3 studies, amlitelimab was well-tolerated, and the safety profile was consistent with previously reported data. In September 2025, Sanofi’s COAST 1 phase 3 study of amlitelimab ...

Investing.com -- UBS downgraded French pharmaceutical giant Sanofi SA (EPA:SASY) to “neutral” from “buy” rating and cut its price target to €88 from €105, citing clinical trial failures and weak ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Driven by R&D, Sanofi is actively enhancing their portfolio management and capital allocation. As of 30 September, 2025, the company experienced 8.7% growth in sales, generating $4.55bn from 12 ...

Sanofi is preparing a renewed acquisition bid for Ocular Therapeutix, Inc., targeting its ophthalmology pipeline and strategic assets. SNY seeks to offset looming Dupixent patent expirations by ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...